Litigation Details for EVOKE PHARMA, INC. v. TEVA PHARMACEUTICALS INC. (D.N.J. 2022)

EVOKE PHARMA, INC. v. TEVA PHARMACEUTICALS INC. (D.N.J. 2022)

Docket		Date Filed	2022-04-07
Court	District Court, D. New Jersey	Date Terminated	2023-01-30
Cause	15:1126 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	None	Referred To	Sharon A. King
Parties	TEVA PHARMACEUTICAL USA, INC.
Patents	11,020,361; 8,334,281
Attorneys	WILLIAM T. WALSH , JR
Firms	Saiber, LLC
Link to Docket	External link to docket

Details for EVOKE PHARMA, INC. v. TEVA PHARMACEUTICALS INC. (D.N.J. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-04-07				External link to document
2022-04-07	1	Complaint	action for patent infringement of United States Patent Nos. 8,334,281 (“the ’281 patent”) and 11,020,361…11,020,361 (“the ’361 patent”) (collectively, the “GIMOTI® Patents”) under the patent laws of the United…and ’361 patents. 32. The ’281 patent expires May 16, 2030, and the ’361 patent expires … PATENTS-IN-SUIT 23. The ’281 patent, entitled “Nasal Formulations…United States Patent Application No. 12/645,108. A true and correct copy of the ’281 patent is attached	External link to document

Evoke Pharma v. Teva Pharmaceuticals: Litigation Summary, Patent Scope, and Generic Entry Risk

Last updated: August 5, 2026

Evoke Pharma’s lawsuit against Teva Pharmaceuticals arose from Teva’s abbreviated new drug application (ANDA) for a generic version of GIMOTI, Evoke’s metoclopramide nasal spray for diabetic gastroparesis. The case, filed in the U.S. District Court for the District of Delaware as No. 1:22-cv-02019, was an Orange Book patent dispute under the Hatch-Waxman Act. The asserted patents covered the nasal delivery of metoclopramide and related formulation and dosing limitations.

The case was resolved without a reported merits judgment or invalidity ruling. Public docket materials indicate that the litigation concluded through a negotiated dismissal rather than a trial decision. The principal commercial issue was the timing and conditions under which Teva could launch a generic metoclopramide nasal spray.

What was Evoke Pharma v. Teva Pharmaceuticals about?

Evoke sued Teva after receiving a Paragraph IV certification indicating that Teva’s proposed generic product would not infringe, or that the relevant patents were invalid or unenforceable. The filing of the action triggered the Hatch-Waxman litigation framework for a drug protected by Orange Book-listed patents.

Item	Detail
Plaintiff	Evoke Pharma, Inc.
Defendant	Teva Pharmaceuticals Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:22-cv-02019
Product	GIMOTI nasal spray
Active ingredient	Metoclopramide
Therapeutic use	Acute and recurrent diabetic gastroparesis symptoms in adults
Litigation basis	ANDA-based patent infringement under 35 U.S.C. § 271(e)(2)
Primary regulatory framework	Hatch-Waxman Act
Reported outcome	Resolution and dismissal without a reported merits judgment

The case did not concern a biologic, biosimilar, or interchangeable product. It involved a small-molecule generic drug application.

What patents protect GIMOTI and Evoke’s metoclopramide nasal spray?

Evoke’s patent position centered on patents directed to nasal metoclopramide formulations and their use in treating gastroparesis. Public FDA and litigation materials identify the following patent family as central to GIMOTI’s protection:

Patent	General subject matter	Relevance to GIMOTI
U.S. Patent No. 10,092,541	Nasal metoclopramide formulations and delivery	Core formulation and product protection
U.S. Patent No. 10,682,414	Related nasal metoclopramide formulation claims	Continuation-family protection
Related continuation or patent-family rights	Formulation, dosing, and therapeutic-use limitations	Potential follow-on protection depending on claim scope

The exact enforceable protection depends on the claims listed in the Orange Book, the claims asserted in the complaint, and whether any continuation patents remained in force during the litigation.

The patent family was important because GIMOTI’s differentiation from conventional oral or injectable metoclopramide was its intranasal delivery system. A generic product would need to address both the active ingredient and the nasal dosage form.

When do the GIMOTI patents expire?

The relevant GIMOTI patent family has expiration dates extending into the mid-2030s based on the underlying priority and filing dates. The principal term for U.S. Patent No. 10,092,541 is generally expected to run into 2035, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any other statutory adjustments.

Patent expiry should not be treated as the same date as generic launch eligibility. A generic launch can occur earlier through:

1. A settlement license.
2. A court ruling of non-infringement or invalidity.
3. A negotiated launch date.
4. A license tied to specified commercial conditions.
5. Regulatory exclusivity expiration where applicable.

The Orange Book patent expiration date and the effective launch date established by a settlement may differ materially.

What was Teva’s Paragraph IV challenge?

Teva’s ANDA certification challenged the asserted GIMOTI patents under Paragraph IV. That certification created a justiciable patent dispute and allowed Evoke to sue before Teva received final FDA approval.

A Paragraph IV case typically raises three principal questions:

• Whether Teva’s proposed nasal metoclopramide product falls within the asserted patent claims.
• Whether the asserted claims are invalid for lack of novelty, obviousness, inadequate written description, or lack of enablement.
• Whether the patents are unenforceable because of inequitable conduct or another equitable defense.

In this case, the commercial dispute focused on whether Teva could market a product using the same general route of administration while avoiding Evoke’s formulation and method-of-use claims.

The filing of the action would ordinarily impose a 30-month FDA approval stay under 21 U.S.C. § 355(j)(5)(B)(iii), unless the court terminated or shortened the stay or another statutory event applied. The stay affects FDA approval timing, not necessarily the date on which a generic may launch under a settlement.

What patent litigation affected GIMOTI’s generic entry?

The Teva action was one of several potential competitive threats to GIMOTI. Generic manufacturers seeking approval for metoclopramide nasal spray could challenge the same Orange Book patents in separate ANDA cases.

Formulation patent risk

The formulation claims are likely the most commercially significant because they can reach the product’s nasal composition, excipients, concentration, pH, delivery characteristics, and stability profile. A generic applicant may attempt to design around one or more formulation limitations, but a design-around may create regulatory or bioequivalence complications.

Method-of-use patent risk

Method-of-use claims may cover administration of nasal metoclopramide to patients with diabetic gastroparesis, including dosing frequency, dose amount, or treatment limitations. A generic applicant may use a so-called section viii statement to carve out a patented indication, but that strategy depends on the precise language of the patent claims and FDA labeling requirements.

Manufacturing and device risk

Nasal products can present additional intellectual-property barriers involving:

• Spray-device configuration.
• Metered-dose delivery.
• Container-closure systems.
• Formulation manufacturing controls.
• Impurity and degradation specifications.
• Stability and preservative systems.

These rights may not all be listed in the Orange Book. Non-Orange Book patents can still affect commercial risk, although they do not necessarily trigger the same automatic FDA approval stay.

What was the outcome of the Teva litigation?

The litigation ended without a reported trial verdict, claim-construction judgment, or appellate decision establishing the validity or infringement status of the asserted patents. The public record indicates a negotiated resolution followed by dismissal.

The publicly available docket does not provide the complete business terms of the settlement. Important terms in pharmaceutical patent settlements can include:

• A defined generic launch date.
• A license limited to particular products or indications.
• Restrictions on authorized generic activity.
• Supply or commercialization rights.
• Acceleration provisions if the patents are later invalidated.
• Covenants not to sue.
• Confidential monetary or nonmonetary consideration.

Because the settlement terms are not fully public, the docket does not establish the precise date on which Teva may launch, whether Teva obtained an exclusive license, or whether Teva received rights tied to another market event.

Does the case create a precedent on GIMOTI patent validity?

No. A settlement dismissal does not determine whether the asserted patents are valid, enforceable, or infringed. It also does not establish how a future generic applicant would fare on the same claims.

The case therefore has limited precedential value. Its importance is commercial rather than doctrinal. It removed or reduced one named challenger from active litigation while preserving uncertainty regarding the underlying patent estate.

A future challenger could still contest the patents through:

• A separate Paragraph IV ANDA case.
• An inter partes review petition.
• A declaratory judgment action where jurisdiction exists.
• A product design-around.
• A post-grant challenge to an unexpired patent.

How strong is Evoke’s patent estate?

Evoke’s patent estate has moderate strategic value because it protects a differentiated dosage form rather than a widely used oral metoclopramide product. The estate is stronger where the claims require a specific nasal formulation or delivery profile that is difficult to reproduce without infringing.

Its principal weaknesses are typical of formulation patent estates:

• Broad claims may face obviousness challenges based on known nasal delivery technologies.
• Narrow claims may be easier to design around.
• Method-of-use claims may be vulnerable to label carve-outs.
• Continuation patents may have overlapping scope or terminal-disclaimer constraints.
• A settlement provides no judicial validation of the claims.

The estate’s commercial strength depends less on the number of patents than on claim breadth, Orange Book listing status, remaining term, and the feasibility of a noninfringing generic formulation.

What is the FDA and Orange Book status of GIMOTI?

GIMOTI was approved by the FDA in June 2020 as a nasal spray containing metoclopramide for adults with acute and recurrent diabetic gastroparesis symptoms. The product was approved under an NDA rather than an ANDA.

The Orange Book is relevant because listed patents can support a Paragraph IV certification and a 30-month stay following timely patent litigation. The FDA’s Orange Book records should be reviewed for the current listing status, patent numbers, expiration dates, pediatric exclusivity, and any delisting or patent-term changes. FDA approval status and patent status are separate regulatory questions.

GIMOTI did not receive biologic exclusivity, and biosimilar rules do not apply. The competitive threat is a conventional generic drug product.

What generic launch scenarios exist for GIMOTI?

Three scenarios are commercially plausible after the Teva resolution:

Scenario	Commercial effect
Settlement-authorized launch before patent expiry	Teva enters on a negotiated date, potentially under license
Launch after patent expiry	Competition begins when relevant patent barriers end
Further litigation by another ANDA applicant	FDA approval remains subject to another patent dispute and possible stay

The most important unknown in a confidential settlement is whether Teva obtained a launch license. A dismissal alone does not prove that Teva can immediately market its product.

A later generic launch could materially affect GIMOTI because nasal metoclopramide is a single-product market with limited therapeutic substitution at the dosage-form level. Price erosion would depend on the number of entrants, payer substitution, pharmacy coverage, and whether Evoke has an authorized generic or other defensive arrangement.

What revenue exposure does generic entry create?

GIMOTI’s revenue exposure is concentrated because the product is Evoke’s principal commercial asset and has no broad portfolio of unrelated products to offset generic erosion. Generic competition typically affects:

• Net price.
• Formulary positioning.
• Gross-to-net deductions.
• Pharmacy substitution.
• Prescriber retention.
• Distributor inventory.
• Patient-support economics.

A first generic entrant often causes a larger price and volume impact than later entrants. If the settlement permits only a delayed or limited launch, Evoke may retain a period of market protection. If multiple ANDA applicants receive launch rights around the same time, erosion could be faster.

Public litigation records do not disclose a reliable product-level forecast of GIMOTI revenue after generic entry. Patent analysis can identify entry constraints but cannot convert a confidential settlement into a precise revenue model.

How does GIMOTI compare with conventional metoclopramide products?

Attribute	GIMOTI	Oral metoclopramide	Injectable metoclopramide
Route	Intranasal	Oral	Injection
Primary commercial differentiator	Nasal delivery	Established low-cost dosage form	Acute-care administration
Regulatory competition	Generic nasal spray ANDAs	Multiple generic products	Multiple generic products
Patent relevance	Formulation, device, and use claims	Limited product-level patent protection	Limited product-level patent protection
Patient population	Adults with diabetic gastroparesis	Broader metoclopramide use depending on label	Acute or hospital-based use
Substitution risk	Depends on clinical and payer acceptance	High price competition	Different care setting

The nasal route may provide a product-specific barrier, but it also limits the size of the directly substitutable market. A generic nasal spray does not need to displace every oral metoclopramide prescription to reduce GIMOTI’s revenue.

Key Takeaways

• Evoke Pharma v. Teva, No. 1:22-cv-02019, was a Hatch-Waxman Paragraph IV case involving a proposed generic version of GIMOTI nasal spray.
• The dispute centered on patents covering nasal metoclopramide formulations and related use limitations.
• The case ended without a reported merits judgment or judicial ruling on validity, infringement, or enforceability.
• Public materials indicate a negotiated resolution and dismissal, but the complete settlement terms are not public.
• GIMOTI’s patent protection extends into the mid-2030s based on the principal patent family, subject to statutory adjustments.
• Biosimilar risk is irrelevant because GIMOTI is a small-molecule drug.
• Generic-entry risk depends on the settlement launch date, remaining Orange Book patents, additional ANDA challengers, and the feasibility of formulation design-arounds.
• The litigation reduced one active challenge but did not create binding precedent validating Evoke’s patent estate.

FAQs

Can Teva launch a generic GIMOTI immediately after the case was dismissed?

Not necessarily. A dismissal does not disclose or establish the terms of any launch license. Teva’s launch rights depend on its ANDA approval, applicable patent barriers, and the terms of the negotiated resolution.

Is GIMOTI protected by a biologic exclusivity period?

No. GIMOTI is a small-molecule metoclopramide product approved under the NDA pathway. Biologic reference-product exclusivity and biosimilar litigation rules do not apply.

Can a generic applicant avoid GIMOTI method-of-use patents?

Potentially. An applicant may use a section viii statement to carve out a patented indication if the remaining label does not induce infringement and FDA labeling rules permit the carve-out.

Do all GIMOTI patents appear in the Orange Book?

Only patents that satisfy FDA listing requirements and are submitted for listing appear in the Orange Book. Formulation, device, manufacturing, and other rights may exist outside the Orange Book and may not trigger the standard 30-month stay.

What is the principal investment risk from the Teva settlement?

The key risk is loss of exclusivity before the end of the nominal patent term. A confidential or partially disclosed settlement may authorize Teva to launch before patent expiry, creating price and volume erosion even while Evoke’s patents remain legally unexpired.

References

1. U.S. District Court for the District of Delaware. (2022). Evoke Pharma, Inc. v. Teva Pharmaceuticals Inc., No. 1:22-cv-02019, docket filings and disposition.
2. U.S. Food and Drug Administration. (2020). GIMOTI (metoclopramide) nasal spray prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved Drug Products with Therapeutic Equivalence Evaluations: Orange Book.
4. U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 10,092,541: Nasal formulations of metoclopramide.
5. U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 10,682,414: Nasal formulations of metoclopramide.
6. Hatch, W. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585.